newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

  • Eikon Therapeutics, Inc. appointed Ching-Pin ("CP") Chang, M.D., Ph.D. as Executive Vice President & Chief Scientific Officer.
  • Dr. Chang brings over two decades of experience in academic medicine, foundational research, & drug discovery.
  • He previously served as Vice President, Head of Cardiovascular Discovery Biology & Translational Pharmacology at Bristol Myers Squibb.
  • Prior to Bristol Myers Squibb, Dr. Chang held leadership roles at Gilead Sciences & MyoKardia, where he helped characterize mavacamten for hypertrophic cardiomyopathy.
  • Dr. Chang's academic career includes establishing a laboratory at Stanford University & holding the Charles Fisch Endowed Chair of Cardiology at Indiana University School of Medicine.
  • He earned his medical degree from National Taiwan University, his Ph.D. in cancer biology from Stanford University, & completed training at Massachusetts General Hospital & the Howard Hughes Medical Institute.
  • Eikon Therapeutics is a late-stage clinical biopharmaceutical company focused on oncology & utilizing a proprietary single molecule tracking system.
  • The company plans to integrate traditional biology research with advanced engineering to develop novel therapeutics for serious unmet medical needs.